Journals / Kocatepe Tıp Dergisi / 2026 / Cilt: 27 Sayı: 2

TREATMENT RESULTS IN COLORECTAL CANCER PATIENTS OVER 75 YEARS OF AGE

75 YAŞ ÜSTÜ KOLOREKTAL KANSERLİ HASTALARDA TEDAVİ SONUÇLARI

Beyza Ünlü(AFYONKARAHISAR HEALTH SCIENCES UNIVERSITY)0000-0002-8178-0277
Sena Ece Davarcı(AFYONKARAHISAR HEALTH SCIENCES UNIVERSITY)0000-0003-1142-9411
Yaşar Culha(Sivas Numune Hospital)0000-0002-0317-7552
Hacer Demir(AFYONKARAHISAR HEALTH SCIENCES UNIVERSITY)0000-0003-1235-9363
Meltem Baykara(AFYONKARAHISAR HEALTH SCIENCES UNIVERSITY)0000-0003-3291-8134
Pages
258–266
Publication Date
2026-04-16
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In stage 2 patients, there was no difference in overall survival (OS) and disease-free survival (DFS) between the group with and without adjuvant therapy (p values 0.133 and 0.937, respectively).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Colorectal cancers are the leading cause of cancer-related deaths and usually occur in advanced age.
📊
Key Findings & Data:In this study, we aimed to retrospectively evaluate the treatment outcomes of colorectal cancer patients over 75 years of age.
💡
Conclusion & Impact:In stage 2 patients, there was no difference in overall survival (OS) and disease-free survival (DFS) between the group with and without adjuvant therapy (p values 0.133 and 0.937, respectively).
🔬Design:Review & Systematic Survey
📍Scope:2009 Verileri
⚙️Variables:Kolorektal kanser · Geriatrik onkoloji · Kemoterapi.

Abstract

OBJECTIVE: Colorectal cancers are the leading cause of cancer-related deaths and usually occur in advanced age. Since geriatric patients are often excluded from most clinical trials, there is insufficient data on the treatment of these patients in the literature. In this study, we aimed to retrospectively evaluate the treatment outcomes of colorectal cancer patients over 75 years of age. MATERIAL AND METHODS: 160 patients aged 75 years and older who were diagnosed between 01.01.2009 and 01.06.2024 and admitted to Afyonkarahisar Health Sciences University Medical Oncology Clinic were included. The files of the patients were retrospectively reviewed and statistical analyses were performed with SPSS program. RESULTS: The median follow-up period was 17.2 months. In stage 2 patients, there was no difference in overall survival (OS) and disease-free survival (DFS) between the group with and without adjuvant therapy (p values 0.133 and 0.937, respectively). In stage 3 patients, adjuvant treatment did not contribute to DFS (p=0.069), but OS (p=0.037). Adding oxaliplatin to adjuvant treatment did not contribute to OS (p=0.692). No OS difference was observed between metastatic first-line treatment regimens (p=0.609). Addition of anti-VEGF or anti-EGFR in the first-line treatment was shown to contribute to PFS (0.009). Addition of anti-VEGF in the right colon and anti-EGFR in the left colon numerically contributed to OS in first-line treatment. CONCLUSIONS: Since most patients over the age of 75 cannot be included in clinical studies due to their comorbidities, the absolute necessity of giving treatment to these patients and which treatment regimens to choose if treatment is given makes clinicians think. This study showed that patients in the geriatric population had treatment outcomes consistent with the literature and concluded that treatment in geriatric patients, who are expected to have a low risk of toxicity, should be planned in accordance with current guideline recommendations.

Özet

AMAÇ: Kolorektal kanserler kansere bağlı ölümlerin önde gelen nedenlerindendir ve genellikle ileri yaşta görülür. Geriatrik hastalar çoğu klinik çalışmaya dahil edilemediği için, literatürde bu hastaların tedavisi ile ilgili yeterli veri yoktur. Bu çalışmada 75 yaş üzeri kolorektal kanser kanseri tanısı olan hastaların tedavi sonuçlarını retrospektif olarak değerlendirmeyi amaçladık. GEREÇ VE YÖNTEM: 01.01.2009 ile 01.06.2024 tarihleri arasında tanı alan ve Afyonkarahisar Sağlık Bilimleri Üniversitesi Tıbbi Onkoloji Kliniği’ne başvuran 75 yaş ve üzeri 160 hasta dahil edildi. Hastaların dosyaları retrospektif olarak incelenerek SPSS programıyla istatistiksel analizleri yapıldı. BULGULAR: Takip süresi medyan 17,2 aydı. Evre 2 hastalarda adjuvan tedavi alan ve almayan grup arasında genel sağkalım (OS) ve hastalıksız sağkalım (DFS) farkı izlenmedi (p değerleri sırasıyla 0,133 ve 0,937). Evre 3 hastalarda adjuvan tedavi verilmesinin DFS katkısı izlenmezken (p=0,069), OS katkısı görüldü (p=0,037). Adjuvan tedaviye oksaliplatin eklenmesinin OS katkısı görülmedi (p=0,692). Metastatik ilk basamak tedavi rejimleri arasında OS farkı izlenmedi (p=0,609). İlk basamakta anti-VEGF ya da anti-EGFR eklemenin PFS katkısı gösterildi (0,009). İlk basamak tedaviye sağ kolonda anti-VEGF eklemenin, sol kolonda ise anti-EGFR eklemenin nümerik olarak OS katkısı vardı. SONUÇ: 75 yaş üzeri çoğu hasta komorbiditeleri nedeni ile klinik çalışmalara dahil edilemediğinden bu hastalara tedavi vermenin mutlak gerekliliği, tedavi verilecekse hangi tedavi rejimlerinin seçileceği klinisyenleri düşündürmektedir. Bu çalışma, geriatrik popülasyondaki hastaların literatürle uyumlu tedavi sonuçlarına sahip olduğunu göstermiş ve toksisite riskinin düşük olması beklenen geriatrik hastalarda tedavinin mevcut kılavuz önerilerine uygun olarak planlanması gerektiği sonucuna varmıştır.

🔖

Cite This Article

Ünlü, B., Davarcı, S. E., Culha, Y., Demir, H., Baykara, M. (2026). TREATMENT RESULTS IN COLORECTAL CANCER PATIENTS OVER 75 YEARS OF AGE. Kocatepe Tıp Dergisi, Cilt: 27 Sayı: 2, 258–266. https://doi.org/10.18229/kocatepetip.1739344

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (27)

  1. Papamichael D, Audisio R, Glimelius B, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Annals of oncology. 2015;26(3):463-76.
  2. Aarts MJ, Lemmens VE, Louwman MW, et al. Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcome. European Journal of Cancer. 2010;46(15):2681-95.
  3. Itatani Y, Kawada K, Sakai Y. Treatment of elderly patients with colorectal cancer. BioMed research international. 2018;11:2176056.
  4. Shen L, Meng K, Wang Y, et al. The clinical features, management, and survival of elderly patients with colorectal cancer. Journal of Gastrointestinal Oncology. 2021;12(1):89.
  5. Sundararajan V, Mitra N, Jacobson JS, et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Annals of Internal Medicine. 2002;136(5):349-57.
  6. Jensen SA, Vilmar A, Sørensen JB. Adjuvant chemotherapy in elderly patients (≥ 75 yr) completely resected for colon cancer stage III compared to younger patients. Medical Oncology. 2006;23(4):521-31.
  7. Sanoff HK, Carpenter WR, Stürmer T, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. Journal of Clinical Oncology. 2012;30(21):2624-34.
  8. Tournigand C, André T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. Journal of clinical oncology. 2012;30(27):3353-60.
  9. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. Journal of clinical oncology. 2011;29(28):3768-74.
  10. Schmoll H-J, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. Journal of Clinical Oncology. 2015;33(32):3733-40.
  11. Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Annals of oncology. 2012;23(5):1190-7.
  12. Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomized, phase 3 trial. The Lancet Oncology. 2011;12(11):1032-44.
  13. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (London, England). 2000;355(9209):1041-7.
  14. Rosati G, Cordio S, Bordonaro R, et al. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Annals of Oncology. 2010;21(4):781-6.
  15. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(2):229-37.
  16. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(22):4866-75.
  17. Sastre J, Aranda E, Massutí B, et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Critical Reviews In Oncology/Hematology. 2009;70(2):134-44.
  18. Mattioli R, Massacesi C, Recchia F, et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Annals of oncology: official journal of the European Society for Medical Oncology. 2005;16(7):1147-51.
  19. Cen P, Liu C, Du XL. Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. Annals of oncology: official journal of the European Society for Medical Oncology. 2012;23(6):1503-11.
  20. Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Annals of oncology: official journal of the European Society for Medical Oncology. 2016;27(1):121-7.
  21. Cassidy J, Saltz LB, Giantonio BJ, et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Journal of cancer research and clinical oncology. 2010;136(5):737-43.
  22. Aranda E, Polo E, Camps C, et al. Treatment patterns for metastatic colorectal cancer in Spain. Clinical and Translational Oncology. 2020;22:1455-62.
  23. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(2):229-37.
  24. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(22):4866-75.
  25. Mattioli R, Massacesi C, Recchia F, et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Annals of oncology: official journal of the European Society for Medical Oncology. 2005;16(7):1147-51.
  26. Cen P, Liu C, Du XL. Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. Annals of oncology: official journal of the European Society for Medical Oncology. 2012;23(6):1503-11.
  27. Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Annals of oncology: official journal of the European Society for Medical Oncology. 2016;27(1):121-7.